| Large-scale clonal analysis resolves aging of the mouse hematopoietic stem cell compartment R Yamamoto, AC Wilkinson, J Ooehara, X Lan, CY Lai, Y Nakauchi, ... Cell stem cell 22 (4), 600-607. e4, 2018 | 173 | 2018 |
| Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia H Zhang, Y Nakauchi, T Köhnke, M Stafford, D Bottomly, R Thomas, ... Nature cancer 1 (8), 826-839, 2020 | 130 | 2020 |
| A safeguard system for induced pluripotent stem cell-derived rejuvenated T cell therapy M Ando, T Nishimura, S Yamazaki, T Yamaguchi, A Kawana-Tachikawa, ... Stem cell reports 5 (4), 597-608, 2015 | 96 | 2015 |
| Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2 R Dutta, TY Zhang, T Köhnke, D Thomas, M Linde, E Gars, M Stafford, ... The Journal of clinical investigation 130 (4), 1843-1849, 2020 | 27 | 2020 |
| Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability D Thomas, M Wu, Y Nakauchi, M Zheng, CAL Thompson-Peach, K Lim, ... Cancer discovery 13 (2), 496-515, 2023 | 22 | 2023 |
| Use of polyvinyl alcohol for chimeric antigen receptor T-cell expansion T Nishimura, I Hsu, DC Martinez-Krams, Y Nakauchi, R Majeti, ... Experimental hematology 80, 16-20, 2019 | 21 | 2019 |
| Concurrent administration of intravenous systemic and intravitreal methotrexate for intraocular lymphoma with central nervous system involvement Y Nakauchi, H Takase, S Sugita, M Mochizuki, S Shibata, Y Ishiwata, ... International journal of hematology 92, 179-185, 2010 | 21 | 2010 |
| The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia Y Nakauchi, A Azizi, D Thomas, MR Corces, A Reinisch, R Sharma, ... Blood cancer discovery 3 (4), 346-367, 2022 | 20 | 2022 |
| Effective treatment against severe graft-versus-host disease with allele-specific anti-HLA monoclonal antibody in a humanized mouse model Y Nakauchi, S Yamazaki, SC Napier, J Usui, Y Ota, S Takahashi, ... Experimental Hematology 43 (2), 79-88. e4, 2015 | 9 | 2015 |
| Reengineering ponatinib to minimize cardiovascular toxicity AP Hnatiuk, AAN Bruyneel, D Tailor, M Pandrala, A Dheeraj, W Li, ... Cancer research 82 (15), 2777-2791, 2022 | 7 | 2022 |
| Genetically corrected RAG2-SCID human hematopoietic stem cells restore V(D)J-recombinase and rescue lymphoid deficiency M Pavel-Dinu, CL Gardner, Y Nakauchi, T Kawai, OM Delmonte, ... Blood Advances 8 (7), 1820-1833, 2024 | 6 | 2024 |
| Establishment of a therapeutic anti-pan HLA-class II monoclonal antibody that directly induces lymphoma cell death via large pore formation S Matsuoka, Y Ishii, A Nakao, M Abe, N Ohtsuji, S Momose, H Jin, ... Plos one 11 (3), e0150496, 2016 | 3 | 2016 |
| RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition AC Fan, Y Nakauchi, L Bai, A Azizi, KA Nuno, F Zhao, T Köhnke, ... The Journal of Clinical Investigation 133 (19), 2023 | 2 | 2023 |
| Induction of Truncating ASXL1 Mutations in Human CD34+ HSPCs Mimics Human ASXL1-Mutated Clonal Hematopoiesis and Progression to Myeloid Malignancies T Koehnke, R Sharma, Y Nakauchi, A Reinisch, R Majeti Blood 134, 820, 2019 | 1 | 2019 |
| IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML D Thomas, Y Nakauchi, M Wu, M Zheng, S Sinha, D Dill, G Peltz, R Majeti Blood 132, 440, 2018 | 1 | 2018 |
| Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis Y Nakauchi, A Ediriwickrema, D Martinez-Krams, F Zhao, A Rangavajhula, ... JoVE (Journal of Visualized Experiments), e65874, 2023 | | 2023 |
| Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML N Landberg, T Koehnke, Y Nakauchi, A Fan, D Karigane, D Thomas, ... Blood 140 (Supplement 1), 2234-2235, 2022 | | 2022 |
| Decreasing the High Risk of Ponatinib-Induced Cardiovascular Toxicity in Chronic Myeloid Leukemia AP Hnatiuk Hnatiuk, AA Bruyneel, D Taylor, M Pandrala, A Dheeraj, W Li, ... Circulation 146 (Suppl_1), A15594-A15594, 2022 | | 2022 |
| Abstract P3105: Improving Cardiovascular Toxicity Of Chronic Myeloid Leukemia Therapy. A Hnatiuk Hnatiuk, A Bruyneel, D Taylor, M Pandrala, R Serrano, D Feyen, ... Circulation Research 131 (Suppl_1), AP3105-AP3105, 2022 | | 2022 |
| The Cell Type–Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia R Sharma, DC Hernandez, T Köhnke, D Karigane, A Fan, ... | | 2022 |
Thomas KöhnkePostdoctoral Scholar在 stanford.edu 的电子邮件经过验证
